| FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE | GlaxoSmithkline | ||
| 100 mcg/62.5 mcg/ 25 mcg ; Powder for Inhalation |
More Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
More Than 5
|
None | ||
| None | None | ||
| TRELEGY ELLIPTA is a combination of fluticasone furoate, an inhaled corticosteroid (ICS); umeclidinium, an anticholinergic; and vilanterol, a long-acting beta2-adrenergic agonist (LABA), indicated for: • the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). • the maintenance treatment of asthma in patients aged 18 years and older. | |||
|
Yes
| |||
| TRELEGY ELLIPTA | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 | Patent 17 | Patent 18 | Patent 19 | Patent 20 | Patent 21 | Patent 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ********* *** ***. | ******* **** **** | ******* **** **** | ******* **** **** | ******* **** **** | ******* **** **** | ******* **** **** | ******* **** **** | ******* **** **** | ******* **** **** | ******* **** **** | ******* **** **** | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | *** ********* | **** ** *** **, **** | |
| ****-************ ********** *********** | ****-************ ********** ********** | ****-************ ********** *********** | ****-************ ********** ********** | ****-************ ********** ********** | ********** ******* *** ********** **************** *********** *** *** ********* ** *********** ******** | **************** *********** *** ********* ** *********** ******** | ********** ************* ******** *********** | ********** ************* ******** *********** | ********** ************* ******** *********** | **************** *********** *** ********* ** *********** ******** | ********** ********* | ********** ************* ******** *********** | ********** ********* | ******* *** *** **** * ********** ********* | ********** ********* | ******** *** *** ** ********** ********* | ************ ** * ********** ******** ********** *** * ****-* ************** ******* | ************ ** * ********** ******** ********** *** * β-* ************** ******* | ************ ** * ********** ******** ********** *** * ****-* ************** ******* | *** ** ***** ****** *** ******** ***/** ********** **************** | ********** ********* | **************** *********** *** ********* ** *********** ******** |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ********* *** ***. | *** \ ********* | *** **, **** | ******* | **** | *** ****** *** **** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|